Evidence map›Paper›PMID 18413427›Full record

ReviewThe Journal of clinical endocrinology and metabolism2008

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

B M K Biller, A B Grossman, P M Stewart, S Melmed, X Bertagna, J Bertherat, M Buchfelder, A Colao, A R Hermus, L J Hofland and 12 more

2 registry-linked trialsOpen access · bronzeAbstract readReviewConsensus Statement
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 275 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 5 pooled it
27.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02160730 phase2terminatednot on this mapstarted 2014, after this paper: background citation

Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

TypeinterventionalSponsorShlomo Melmed, MDRan2014 to 2018Enrolled4ConditionsCushings DiseaseArmsR-roscovitine
NCT06701838 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease

TypeobservationalSponsorImperial College LondonRan2024 to 2026Enrolled15ConditionsCushing&#39, s Disease, Hypercortisolism, Pituitary AdenomaArms11C-Methionine PET/CT
3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 5 syntheses or guidelines pooled it, 855 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.The Journal of clinical endocrinology and metabolism · 2022
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 19 institutions in 7 countries.

B M K BillerInstitute of Internal Medicine, Division of Endocrinology, School of Medicine, Polytechnic University of Marche, Torrette, Ancona, Italy.
A B Grossman
P M Stewart
S Melmed
X Bertagna
J Bertherat
M Buchfelder
A Colao
A R Hermus
L J Hofland
A Klibanski
A Lacroix
J R Lindsay
J Newell-Price
L K Nieman
S Petersenn
N Sonino
G K Stalla
B Swearingen
M L Vance
J A H Wass
M Boscaro
Massachusetts General Hospital · USAssistance Publique – Hôpitaux de Paris · FRAltnagelvin Area Hospital · GBCedars-Sinai Medical Center · USCentre Hospitalier de l’Université de Montréal · CAChurchill Hospital · GBErasmus MC · NLFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMarche Polytechnic University · ITMax Planck Institute of Psychiatry · DENational Institutes of Health · USRadboud University Medical Center · NLSt Bartholomew's Hospital · GBUniversity of Birmingham · GBUniversity of Duisburg-Essen · DEUniversity of Naples Federico II · ITUniversity of Padua · ITUniversity of Sheffield · GBUniversity of Virginia Health System · US

Funding

The differential diagnosis and treatment of Cushing's syndromeZIAHD008833 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI NIEMAN, LYNNETTE · 2009 to 2015
$2.5M
The differential diagnosis and treatment of Cushing's syndromeZ01HD008833 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI NIEMAN, LYNNETTE K · 2007 to 2008
$838k
Intramural NIH HHS Z01 HD008833
6 · The paper itself

Abstract

objectiveOur objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder.

participantsThirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority.

conclusionsACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.

Indexed as

ACTH Syndrome, EctopicAdrenalectomyAdrenal InsufficiencyAdrenocorticotropic HormoneCushing SyndromeHumansHypophysectomyMetyraponeMitotaneNelson SyndromeAdrenocorticotropic HormoneMetyraponeMitotane

Identifiers

PMID18413427
PMCPMC3214276
OpenAlexW2147573461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.